Pelion S.A. Revenue and Competitors
Estimated Revenue & Valuation
- Pelion S.A.'s estimated annual revenue is currently $22.7M per year.
- Pelion S.A.'s estimated revenue per employee is $201,000
Employee Data
- Pelion S.A. has 113 Employees.
- Pelion S.A. grew their employee count by 8% last year.
Pelion S.A.'s People
Name | Title | Email/Phone |
---|
Pelion S.A. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $23.3M | 116 | -1% | N/A | N/A |
#2 | $80.6M | 401 | 31% | N/A | N/A |
#3 | $21.7M | 108 | 37% | N/A | N/A |
#4 | $34.8M | 173 | 7% | N/A | N/A |
#5 | $231.2M | 1150 | 12% | N/A | N/A |
#6 | $38.2M | 190 | 38% | N/A | N/A |
#7 | $22.7M | 113 | 8% | N/A | N/A |
#8 | $29.1M | 145 | 49% | N/A | N/A |
#9 | $27.5M | 137 | 25% | N/A | N/A |
#10 | $45.6M | 227 | 31% | N/A | N/A |
What Is Pelion S.A.?
Pelion S.A., formerly Polska Grupa Farmaceutyczna S.A., has been present on the market for twenty-five years now. Today, the Pelion Healthcare Group is one of the largest groups operating on the healthcare markets in Poland, Lithuania, and the United Kingdom. Its services cover all market segments (wholesale, retail sale and sale to hospitals) and are targeted at individual patients, pharmacies, hospitals and manufacturers. As a holding company, Pelion S.A. carries out the owner's supervision over all areas of the Group's operations, which are managed by Polska Grupa Farmaceutyczna S.A. (wholesale), Pharmapoint Sp. z o.o. (pre-wholesale), PGF Urtica Sp. z o.o. (hospital supplies), CEPD N.V. (retail), and Pharmalink Sp. z o.o. (services for manufacturers).
keywords:N/AN/A
Total Funding
113
Number of Employees
$22.7M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 113 | 5% | N/A |
#2 | $14.3M | 119 | 17% | N/A |
#3 | N/A | 137 | 21% | N/A |
#4 | $27.3M | 142 | 18% | N/A |
#5 | N/A | 148 | 5% | N/A |